908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M

908 Devices Inc.

Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).
Q4 gross margin improved to 58% from 49%; installed base expanded to 1,935 devices.
Cash $224M at year-end; debt outstanding $15M.
FY 2022 revenue outlook $52M-$55M, representing 23%-30% growth over FY 2021.
Commercial traction with all top 20 biopharma; Tony Hunt (Repligen CEO) added to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.